Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication.
Following surgical resection of Dukes' B or C colorectal cancers 72 patients have been randomly allocated to receive: 5-fluorouracil; or 5-fluorouracil and levamisole; or no treatment. Adjuvant treatment was continued for one year. 66 patients remain evaluable for up to 24 months. Preliminary results show no significant differences in survival or recurrence rates. Two patients receiving 5-fluorouracil and levamisole developed severe, but reversible, neutropenia. Other side effects were uncommon.
D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use; D009503:Neutropenia / Q000139:chemically induced; D011379:Prognosis; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000628:therapy*
D007978:Levamisole; D005472:Fluorouracil